Long-term follow-up of primary mediastinal tumor surgery by a surgeon team
FU Hao,CHEN Keneng,LIANG Zhen,XIONG Hongchao,KANG Xiaozheng,DAI Liang,YAN Wanpu,YANG Yongbo,YANG Heli,QING Bin
DOI: https://doi.org/10.3969/j.issn.1000-8179.20130208
2014-01-01
Chinese Journal of Clinical Oncology
Abstract:Objective:Mediastinal tumors are tumors derived from different organs. Due to its rarity, few clinical consensuses on its diagnosis and treatments have been concluded. This paper aims to summarize the experiences of a single-surgeon team on the surgi-cal treatment of primary medisatinal tumors. Methods:Clinical data were collected from a prospective database between January 2000 and January 2014. The analyses were mainly focused on the long-term survival of 190 cases that underwent radical resectioning surger-ies. Results:The three most common mediastinal tumors are thymic epithelial tumors in 95 cases (50%), neurogenic tumors in 26 cases (13.7%), and mediastinal germ cell tumors in 26 cases (13.7%). Of the 190 patients, 179 patients achieved the R0 resection criterion (94.2%), 8 underwent R2 resectioning (4.2%) and 3 underwent only exploration (1.6%), with 2 cases of death in the 30 days after the surgery. The 1-, 3-, and 5-year survival rates of the thymic epithelial tumor patients were 95%, 92.7%, and 85.7%, respectively. Accord-ing to the Masaoka-Koga staging, the 5-year survival rates of stageⅠ,Ⅱ,Ⅲ, andⅣthymic epithelial tumors are 100%, 82.1%, 90%, and 37.5%, respectively. A multivariate analysis reveals that the Masaoka-Koga staging of thymic epithelial tumors is an independent prognostic factor (P<0.05). According to pathological classification, the 5-year survival rates for A+AB+B1 versus B2+B3 type thymo-ma were 88.6%versus 76.9%, which is statistically significant (P<0.05). Most of the neurogenic tumors are benign, all suffer R0 resec-tioning, and have long term survival. Conclusion:Due to the complexity caused by its histology, the treatment of mediastinal tumors should be based on the origin, nature, location, and size of the tumors. Although the patients of the group have a favorable prognosis, it is difficult to draw conclusions from the studies because of its retrospective characteristics and small sample size. Therefore, to get bet-ter clinical evidence, a multi-center, large sample, and prospective clinical study should be performed.